Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Form 8-K reporting a Nasdaq listing transfer approval. The event occurred on July 3, 2023; the report was signed on July 5, 2023. The filing does not cover a quarterly or annual financial reporting period.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity balances, or other financial metrics.
Material Change Versus Prior Period
Nasdaq approved the Company’s application to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market. The transfer was scheduled to take effect at the opening of business on July 6, 2023. The trading symbol remains APRE.
Outlook, Risks, and Unusual Items
The filing contains general forward-looking statement disclosures concerning study analyses, clinical trials, regulatory submissions, and projected cash position, but it provides no specific financial guidance or quantified outlook.
- Identified risks include the success and timing of clinical trials and other studies.
- Additional risks include geopolitical, economic, business, and competitive factors and uncertainty in estimates of financial performance.
- The Company refers investors to its other SEC filings for additional risk factors and states that actual results may differ materially from forward-looking statements.
- The Company disclaims any obligation to update forward-looking statements.
Facts for Investors to Verify
- Confirm that the Nasdaq transfer became effective at the July 6, 2023 market opening.
- Review subsequent filings for any effects of the transfer on listing compliance, trading, or shareholder matters.
- Consult the Company’s latest periodic filing for cash, liquidity, debt, operating results, and clinical-program updates, none of which are provided in this 8-K.
- Review referenced SEC filings for the Company’s detailed risk factors and projected cash position.